Acute Promyelocytic Leukemia clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
open to eligible people ages 18-71
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Irvine, California and other locations
Our lead scientists for Acute Promyelocytic Leukemia research studies include Kiran Naqvi.
Last updated: